EP2422783A1 — Pharmaceutical Composition
Assigned to Sumitomo Pharma Co Ltd · Expires 2012-02-29 · 14y expired
What this patent protects
The present application provides an oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1): a pregelatinized …
USPTO Abstract
The present application provides an oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1): a pregelatinized starch, a water-soluble excipient, a water-soluble polymer binder and a disintegrant; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation; and wherein the disintegrant is one or more disintegrants selected from the group consisting of corn starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose ca lcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium and crospovidone.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.